ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manus_Nat Med_NOVOAB_ChemRxiv.pdf (563.32 kB)
0/0

Fast Restoration of a Broad-Spectrum SARS-Cov Therapeutic Antibody for SARS-Cov-2

preprint
revised on 11.09.2020 and posted on 14.09.2020 by Sara Zhang, Mike Young, Jason Pan

The rapid spread of SARS-Cov-2 remains a major threat for public health and global economy, both preventative and therapeutic solutions are therefore urgently needed. Through the use of epitope-guided antibody design, we successfully restored a broad-spectrum SARS-Cov therapeutic antibody for SARS-Cov-2. Compared to the precursor antibody CR3022, the newly designed antibody NOVOAB-20 binds to SARS-Cov-2 receptor binding domain (RBD) with a more than 10-fold higher affinity. Because this antibody targets a highly conserved epitope and the mutations on SARS-Cov-2 known so far are all not in this region, it also has the potential to block future SARS-Cov-2 mutants. As a fully humanized antibody, NOVOAB-20 is a promising candidate to be developed as potential therapeutics for SARS-Cov-2, either as monotherapy or in combination with other neutralizing antibodies targeting different epitopes (e.g. the ACE2 binding site).

History

Email Address of Submitting Author

cs@novoab.com

Institution

NovoAb Bioanalytics, Inc.

Country

Canada

ORCID For Submitting Author

0000-0002-0310-2227

Declaration of Conflict of Interest

No conflict of interest

Version Notes

Manus_Nature Med_NOVOAB_ChemRxiv_v1

Exports